Clinical trial on Limiron Tablet for evaluation of iron deficiency anemia

Randomised Open Prospective Clinical study to evaluate the efficacy of Limiron Tab. in Iron Deficiency Anaemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009414

Enrollment

Registered

2017-08-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Iron Deficiency Anaemia

Interventions

Intervention1: Nil: Nil Intervention2: Limiron: 500 mg BD for 2 months Intervention3: Nil: Nil Intervention4: Limiron: 500 mg BD for 2 months (Orally and before meals) Intervention5: NIL: NIL Interven

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age- 14 to 55 yrs. 2. Sex- Male and Female 3. Classical Signs and Symptoms of Anaemia Hb gm%- In Males- 6 to 11 and In Females- 6 to 10 4. Sr. Iron level -For Both- Below 50 mcg/dl 5. Sr. Ferritin level-In Males- Below 24 ng/ml In Females- Below 11 ng/ml

Exclusion criteria

Exclusion criteria: 1. Patients above 55 yrs. and below 14 yrs. of age 2. Pregnant and Lactating mothers 3. Patients with HBsAg positivity and HIV Positivity 4. Patients having malignancy 5. Anaemia, as a symptom of another disease Thalassaemic-syndrome, Megaloblastic Anaemia, Aplastic Anaemia, Congenital Anaemia, Hemolytic Anaemia 6. Patients with Psychoses 7. Patients with Surgical pathology

Design outcomes

Primary

Measure	Time frame
Serum Hb, Serum Iron, Serum Ferritin, CBCTimepoint: 4 weeks	—

Secondary

Measure	Time frame
Serum Hb, Serum Iron, Serum Ferritin, CBCTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Parulkar Geeta Deodatt

Department of Kayachikitsa, R.A. Podar Medical College, Worli, Mumbai-18

geeta.parulkar@gmail.com8652694332

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026